

AD_____

Award Number: W81XWH-08-1-0673

TITLE: Engineer Novel Anticancer Bioagents

PRINCIPAL INVESTIGATOR:

Yiqiang Cheng, Ph.D. (Principal Investigator)
Cheng Wang, Ph.D. (Postdoctoral Research Associate)
Shane Wesener, M.S. (Graduate Research Assistant)
Vishwakanth Potharla, M.S. (Graduate Research Associate)

CONTRACTING ORGANIZATION: University of Wisconsin-Milwaukee
Milwaukee, Wisconsin 53211

REPORT DATE: October 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

✓ Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-10-2009		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15 Sept 2008 – 14 Sept 2009	
4. TITLE AND SUBTITLE Engineer Novel Anticancer Bioagents				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0673	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Yiqiang Cheng (Principal Investigator) Cheng Wang (Postdoctoral Research Associate) Shane Wesener (Graduate Research Assistant) Vishwakanth Potharla (Graduate Research Assistant)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Wisconsin System Milwaukee, Wisconsin 53211				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Material Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Our research in the first contract-year has resulted in: (1) the confirmation of a redox enzyme (encoded by <i>depH</i>) responsible for a critical disulfide bond formation as the final step in FK228 biosynthesis (a publication is appended), (2) the identification of an unexpected pathway regulatory gene <i>depR</i> (previously annotated as <i>orf18</i>) (a manuscript is in preparation), and (3) the successful reconstitution of FK228 biosynthetic gene cluster on three vectors in an <i>E. coli</i> strain, and the detection of heterologous FK228 production in <i>E. coli</i> under both aerobic and anaerobic growth conditions (another manuscript is in preparation as well). Attempt to integrate the complete FK228 biosynthetic gene cluster into the <i>E. coli</i> chromosome for stable functioning without antibiotic selection is in progress. We therefore have achieved the project milestone with some adjustments of the experimental approach and research content.					
15. SUBJECT TERMS FK228 biosynthesis, biosynthetic gene cluster, <i>E. coli</i> , reconstitution, heterologous production					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 21	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4-7
Key Research Accomplishments.....	4-7
Reportable Outcomes.....	7
Conclusion.....	7
References.....	7
Appendices.....	7-21

Introduction


Our awarded research project is to engineer the next generation of novel anticancer bio-agents that will target and eradicate a broad spectrum of solid tumors including breast cancer. Our research design was based on the hypotheses that (1) the next generation of bio-agents could be engineered to continuously produce doses of an anticancer drug (specifically FK228) at the sites of bacterial spore germination and vegetative growth in the hypoxic/necrotic regions of solid tumors, and (2) that the synergistic actions of bacterial consumption of tumor mass and anticancer drug activities could destroy many kinds of solid tumors regardless of cancer genotype, without the need for prodrug injections and could overcome the common side effects and less efficacy of current cancer therapies.

The project has three specific aims, corresponding to three tasks defined in the *State of Work*, with each aim/task to be accomplished in each of the three-contract year duration. The first two aims/tasks are: (1) to reconstitute the FK228 biosynthetic gene cluster and engineer complete expression cassettes, and (2) to transfer the expression cassettes into the *E. coli* strains as pilot experiments. Our research in the first contract-year has achieved those aims/tasks with some adjustments of the experimental approach and research content.

Key Research Accomplishments


1. *Confirmation of a redox enzyme (encoded by *depH*) responsible for a critical disulfide bond formation as the final step in FK228 biosynthesis.*

In our previous work, we cloned the FK228 biosynthetic gene cluster and proposed a working model for FK228 biosynthesis in which a putative FAD-dependent pyridine nucleotide-disulfide oxidoreductase encoded by *depH* gene catalyzes a disulfide bond formation as the final step of FK228 biosynthesis (Cheng, Yang et al. 2007). In this work (as a continuation of the previous work), we validated this point of hypothesis by genetic and biochemical studies. First, bioinformatic analysis of DepH protein sequence indicated that DepH is a redox enzyme that contains an FAD-binding domain, an NADP⁺-binding domain, and a redox motif consisting of two cysteine residues separated by two less conserved amino acids (CxxC). Second, we created a mutant strain by deleting the *depH* gene and found that deletion of *depH* gene severely impaired FK228 production in the mutant strain (~20% of FK228 production level remains, probably due to spontaneous chemical oxidation). Complementation of the mutant with a functional *depH* completely restored FK228 production. Furthermore, an FK228 precursor (intermediate) with a +2 *m/z* shift was detected by LC-MS in the mutant extract. Those observations suggested a definite role of DepH for FK228 biosynthesis, likely involved in the conversion of the precursor (reduced FK228 with two free thiol groups) to FK228. Finally, we overexpressed the *depH* gene and purified DepH protein from *E. coli* culture; we performed extensive in vitro assays to determine the presence of an FAD factor in DepH holo-enzyme, the enzyme kinetic parameters and the redox reactions (**Fig. 1**). Collectively this work represents the first genetic and biochemical study of a rare disulfide bond formation in natural products produced by bacteria. An article has been published in the journal of *Chemistry & Biology* (Wang, Wesener et al. 2009).



2. Identification of an unexpected pathway regulatory gene *depR* (previously annotated as *orf18*)

Also in our previous work, we predicted, largely based on bioinformatic analysis of gene/deduced protein sequences, that the FK228 biosynthetic gene cluster contains a pathway regulatory gene *depL* (encoding a MarR-family transcriptional regulator), and the *orf18* (encoding a hydrogen peroxide-inducible transcriptional activator) is beyond the gene cluster boundary (Cheng, Yang et al. 2007). In this work (as a continuation of the previous work), we discovered, through systematic gene mutation and quantitation of FK228 production in mutant strains, that *depL* plays only a minor role in FK228 production because deletion of *depL* resulted in just a slight reduction of FK228 production (~75% of the wild type level); while that, in contrast, *orf18* (now renamed as *depR*) plays a major role in regulating FK228 production because deletion of *orf18/depR* completely abolished FK228 production and complementation of the *orf18/depR*-mutant restored full FK228 production (**Fig. 2**). Further RT-PCR analysis confirmed that none of the *dep*-genes was actively expressed in the *orf18/depR*-deletion mutant. We have consequently redesigned the downstream experiment. A manuscript is in preparation and will be submitted for publication very soon (Potharla et al, expected in early 2010).




3. Successful reconstitution of FK228 biosynthetic gene cluster on three vectors in an *E. coli* strain and the detection of heterologous FK228 production in *E. coli* under both aerobic and anaerobic growth conditions

Because of the unexpected identification of *orf18/depR* as a major pathway regulator of FK228 biosynthesis, we decided to take a cautious step to verify whether all genes required for FK228 have been identified. Instead of taking a great leap to reconstitute the entire FK228 biosynthetic gene cluster into one expression cassette, we designed a new and quick approach to test whether FK228 can be produced in *E. coli* (**Fig. 3A**). In this design, a schematic *E. coli* cell contains three compatible and self-replicable constructs:

- (1) Cosmid 18 is the originally reported construct that contains the *dep* gene cluster and flanking DNAs (Cheng, Yang et al. 2007). Cosmid 18 has a pUC origin of replication and contains both an ampicillin-resistance marker gene and a kanamycin-resistance marker gene. However, expression of the *dep*-genes on Cosmid 18 requires a functional *orf18/depR* [see following (3)].
- (2) Construct pCDFDuet-X-Y is a dual expression vector carrying a combination of two heterologous genes (X = *sfp*; Y = *fabD1* or *fabD2*) necessary for FK228 biosynthesis. Gene *sfp* encodes an Sfp-type phosphopantetheinyl transferase (PPTase) to covert all carrier proteins (ACPs and PCPs) from apo-form into holo-form by attaching a flexible phosphopantetheinyl

arm. Both gene *fabD1* and *fabD2* encode a malonyl CoA acyltransferase (MCAT) that participates in fatty acid biosynthesis, but is also involved in FK228 biosynthesis (as proven in this experiment). pCDFDuet-X-Y has a CDF origin of replication and contains a streptomycin-resistance marker gene. The expression of heterologous genes is inducible by IPTG.

- (3) Although *orf18/depR* resides on Cosmid 18, it is not expressed due to the fact the promoter region of the operon which *orf18/depR* resides is missing (Cheng, Yang et al. 2007). Therefore we decided to add yet another construct which carries *orf18/depR* on a lactose-inducible vector pBMTL-3. This vector has a broad host-range, has a pBBR1 origin of replication and contains a chloramphenicol-resistance gene (Lynch and Gill 2006).



This recombinant *E. coli* strain was cultivated in LB medium supplemented with appropriate concentrations of antibiotics (25 μ g/ml kanamycin, 100 μ g/ml streptomycin, and 10 μ g/ml chloramphenicol) under anaerobic or aerobic conditions at room temperature without agitation. IPTG (0.5 mM final concentration) and lactose (2% final concentration) were added to cultures at 12 hours and the cultures were allowed to grow for three more days. Resins (as absorbent for FK228) and cells were harvested by centrifugation, freeze-dried, and eluted with ethyl acetate. Organic extracts were concentrated with a rotary evaporation and subjected to LC-MS analysis (**Fig. 3B** and **3C**). To our delight, FK228 was produced by the *E. coli* strain under both anaerobic and aerobic conditions. We estimated that FK228 was produced at approximately 0.4 mg/L (740 nM) concentration under anaerobic growth conditions, which is about 1/10 of the FK228 concentration produced under aerobic growth conditions. Since FK228 was reported to exert potent anticancer activities from high nM to low μ M range of concentrations by intravenous injection during clinical trials (NCI 2009), our result appears to be very promising because 740 nM concentration of FK228 should be sufficient to elicit anticancer efficacy especially when FK228 is produced de novo inside a solid tumor. Nevertheless, we still hope to increase the FK228 titer by optimize the IPTG/lactose induction ratio and timing, and

by integrating the gene cluster into host chromosome. Another manuscript is in preparation and will be submitted for publication within six months (Wesener et al, expected in mid-2010).

Reportable Outcomes:

1. One paper was published in June 2009 (Wang, Wesener et al. 2009) (attached as an appendix).
2. One manuscript is in preparation and will be submitted for publication within two months.
3. One more manuscript is in preparation and will be submitted for publication within six months.

Conclusion

We have reconstituted the FK228 biosynthetic gene cluster on three plasmids in an *E. coli* strain and the recombinant strain produced FK228 under both anaerobic and aerobic growth conditions. We estimated that FK228 was produced at about 0.4 mg/L (740 nM) concentration under anaerobic conditions; this concentration should be sufficient to elicit anticancer efficacy especially when FK228 is produced de novo inside a solid tumor. Attempt to integrate the complete FK228 biosynthetic gene cluster into the *E. coli* chromosome for stable functioning without antibiotic selection is in progress. We therefore have achieved the project milestone with some adjustments of the experimental approach and research content.

References

- Cheng, Y. Q., M. Yang, et al. (2007). "Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in *Chromobacterium violaceum* No. 968." *Appl Environ Microbiol* **73**(11): 3460-9.
- Lynch, M. D. and R. T. Gill (2006). "Broad host range vectors for stable genomic library construction." *Biotechnol Bioeng* **94**(1): 151-8.
- NCI (2009). U.S. National Institute of Health. <http://clinicaltrials.gov/ct2/results?term=depsipeptide>.
- Wang, C., S. R. Wesener, et al. (2009). "An FAD-dependent pyridine nucleotide-disulfide oxidoreductase is involved in disulfide bond formation in FK228 anticancer depsipeptide." *Chem Biol* **16**(6): 585-93.

Appendix

Our published paper: Wang, C., S. R. Wesener, et al. (2009). "An FAD-dependent pyridine nucleotide-disulfide oxidoreductase is involved in disulfide bond formation in FK228 anticancer depsipeptide." *Chem Biol* **16**(6): 585-93.

An FAD-Dependent Pyridine Nucleotide-Disulfide Oxidoreductase Is Involved in Disulfide Bond Formation in FK228 Anticancer Depsipeptide

Cheng Wang,¹ Shane R. Wesener,¹ Hailong Zhang,¹ and Yi-Qiang Cheng^{1,2,*}

¹Department of Biological Sciences

²Department of Chemistry and Biochemistry

University of Wisconsin-Milwaukee, PO Box 413, Milwaukee, WI 53201, USA

*Correspondence: yqcheng@uwm.edu

DOI 10.1016/j.chembiol.2009.05.005

SUMMARY

Disulfide bonds are rare in bacterial natural products, and the mechanism of disulfide bond formation in those products is unknown. Here we characterize a gene and its product critical for a disulfide bond formation in FK228 anticancer depsipeptide in *Chromobacterium violaceum*. Deletion of *depH* drastically reduced FK228 production, whereas complementation of the *depH*-deletion mutant with a copy of *depH* on a medium copy-number plasmid not only fully restored the FK228 production but also significantly increased the FK228 yield. Purified 6xHis-tagged DepH fusion protein in native form is a homodimer of 71.0 kDa, with each monomer containing one molecule of FAD. DepH efficiently converts an immediate FK228 precursor to FK228 in the presence of NADP⁺. We conclude that DepH is an FAD-dependent pyridine nucleotide-disulfide oxidoreductase, specifically and efficiently catalyzing a disulfide bond formation in FK228.

INTRODUCTION

Disulfide bonds that link two nonadjacent cysteine residues often exist in ribosomally synthesized proteins and peptides as well as their derived products, such as lantibiotics, toxins, venoms, and hormones, to maintain proper folding configuration, to mediate redox cycling of enzyme activity, or to regulate a protein's activation and deactivation (Giles et al., 2003; Kado-kura et al., 2003). Proteins that are capable of catalyzing protein/peptide disulfide bond formation are members of a large collection of thiol-disulfide oxidoreductases found in all living cells. Many of these enzymes belong to the thioredoxin superfamily, which is defined by an active site containing a CXXC redox motif (cysteines separated by two amino acids) and by a thioredoxin fold seen in three-dimensional structure of the prototypical thioredoxin 1 of *E. coli* (Lennon et al., 1999; Waksman et al., 1994). The most studied catalysts for disulfide bond formation are the Dsb-family of proteins (DsbA, DsbB, DsbC, and DsbD) of *E. coli* (Bardwell et al., 1991; Martin et al., 1993; Nakamoto and Bardwell, 2004). Other enzymes that are not members of the

thioredoxin superfamily but use redox active cysteine residues in transferring electrons in oxidative and reductive pathways have entirely different three-dimensional structures from thioredoxin. They might use small molecule electron donors and acceptors, such as FAD, NAD⁺/NADH, NADP⁺/NADPH, quinone, or lipoic acid (Bryk et al., 2002).

Disulfide bonds are also found in small molecules (natural products) made nonribosomally by a series of biochemical reactions catalyzed by enzymes other than the ribosomal machinery. Most of those natural products are produced by garlic plants or fungi (Jacob, 2006) and a few are produced by bacteria (Figure 1), but the enzymology of disulfide bond formation in those products is largely unknown. Based on a study of heterologous production of echinomycin in *E. coli*, Watanabe et al. proposed the Ecm17 protein (encoded by *ecm17* gene in the echinomycin biosynthetic gene cluster) as an oxidoreductase that catalyzes the formation of a disulfide bond in a triostin A precursor to afford triostin A (Watanabe et al., 2006), but there was no biochemical evidence to support this plausible notion. Disulfide bond in triostin A is not critical for bioactivities because it can be further modified by a SAM-dependent methyltransferase to form a thioacetal bond in the final product echinomycin. Triostin A is a member of the quinoxaline family of antibiotics that also include BE-22179, SW-163C, and thiocoraline (Dawson et al., 2007) (Figure 1). There is no molecular genetic study of the biosynthesis of BE-22179 or SW-163C. Surprisingly the thiocoraline biosynthetic gene cluster does not contain a gene encoding an Ecm17-like enzyme or, in a broad sense, a thioredoxin-like oxidoreductase (Lombo et al., 2006). It is unclear whether the disulfide bond in thiocoraline is formed by an unidentified enzyme encoded by a gene independent of the gene cluster or simply by chemical oxidation. Finally, the biogenesis of a disulfide bond in FR901,375 (Masakuni et al., 1991), spiruchostatins (Masuoka et al., 2001), somocystinamide A (Nogle and Gerwick, 2002), or a dithiolane bond in leinamycin (Tang et al., 2004), remains to be elucidated.

FK228 (depsipeptide; Figure 1) is a rare disulfide-containing natural product produced by Gram-negative *Chromobacterium violaceum* No. 968 as a prodrug (Shigematsu et al., 1994; Ueda et al., 1994). Prodrug FK228 can diffuse across the cell membrane and be readily activated by intracellular reduction of the disulfide bond inside the cytoplasmic environment of mammalian cells. Upon activation, the freed thiol group on the longer aliphatic tail of reduced FK228 fits inside the catalytic pocket of preferred class I histone deacetylases (HDACs),




Figure 1. FK228 Biosynthetic Gene Cluster and Structures of Disulfide- or Dithiolane-Containing Natural Products Produced Nonribosomally by Bacteria

Gene *depH* is depicted as one of the three post-nonribosomal peptide synthetase (NRPS; dark red)/polyketide synthase (PKS; orange) tailoring genes (yellow). All natural products listed here have and are expected to have anticancer activities. Conceptual conversions from precursor (the immediate precursor of FK228 or triostin A) to product (FK228 or triostin A) by enzyme (DepH or Ecm17, respectively) are indicated. Disulfide and dithiolane bonds are highlighted by a yellow oval background shading.

bond as the final step of FK228 biosynthesis (Cheng et al., 2007). Primary sequence of DepH shares a 72% identity/85% similarity to a hypothetical protein (GenBank accession number

ABC38333; named TdpH in our ongoing work) of *Burkholderia thailandensis* E264 (Kim et al., 2005), and shares modest percentages of identity/similarity to a few hypothetical proteins of *Pseudomonas*, *Sinorhizobium*, or *Cellvibrio* species. Neither the DepH nor the TdpH sequence has more than 34% identity/46% similarity to the deduced Ecm17 sequence of the *ecm17* gene in the triostin A/echinomycin biosynthetic gene cluster in *S. lasaliensis* (Watanabe et al., 2006). A phylogenetic analysis of the sequences of DepH and its closest homologs, and other well-studied proteins involved in disulfide bond formation in proteogenic products, suggests that an active site containing a CXXC redox motif is conserved in all related proteins; but DepH, TdpH, Ecm17 and a few hypothetical proteins constitute a distinctive clade (group 1) of proteins with a CPY/FC motif, which is clearly different from that (CAT/VC) of the thioredoxin reductase (TrxB/TrxR) family of enzymes (group 2) or that (CXXC; X represents any less conserved residue) of the Dsb-family of enzymes (group 3) (Figure 2A). Site-directed mutagenesis experiments have confirmed the catalytic essentiality of both cysteine residues in the CPYC redox motif of DepH (see Enzyme Activity and Kinetics). Furthermore, DepH can be dissected into an FAD-binding domain, an NADP⁺/NADPH-binding domain and two terminal regions, according to its organizational similarity to the TrxR of *Mycobacterium tuberculosis* (Akif et al., 2005) (Figure 2B).

chelating Zn²⁺, and partially inhibits the enzyme activities (Nakajima et al., 1998). Selective but modest inhibition of HDACs leads to a cascade of chromatin remodeling, tumor suppressor gene reactivation, apoptosis, and regression of cancer (Bolden et al., 2006). FK228 has become one of the most promising anticancer agents specifically intervening cancer epigenetics (Yoo and Jones, 2006). Aimed at diversification and optimization of FK228 through metabolic engineering, combinatorial biosynthesis, and chemo-enzymatic synthesis, we previously cloned and partially characterized the FK228 biosynthetic gene cluster (designated as *dep* for depsipeptide). Based on the deduced protein functions of *dep* genes, we proposed an unusual hybrid nonribosomal peptide synthetase (NRPS)-polyketide synthase-NRPS pathway for FK228 biosynthesis in *C. violaceum* no. 968 (Cheng et al., 2007). This pathway would lead to the production of an immediate FK228 precursor (reduced FK228) with two free thiol groups from cysteine residues (Figure 1). Furthermore, we proposed DepH as a putative FAD-dependent pyridine nucleotide-disulfide oxidoreductase, encoded by *depH*, to catalyze a disulfide bond formation between two thiol groups as the final step in FK228 biosynthesis.

Here we report genetic and biochemical evidence in support of DepH as an FAD-dependent pyridine nucleotide-disulfide oxidoreductase, specifically and efficiently catalyzing a disulfide bond formation in FK228. To our best knowledge, this work represents the first biochemical characterization of an enzyme involved in the formation of a disulfide bond in a nonribosomally produced bacterial natural product.

RESULTS

Protein Sequence Analysis of DepH

Gene *depH* in the FK228 biosynthetic gene cluster has an open reading frame (ORF) of 960 bp and was predicted to encode a 319-amino-acid FAD-dependent pyridine nucleotide-disulfide oxidoreductase, DepH (GenBank accession number ABP57752), that converts two thiol groups from cysteines into a disulfide

bond as the final step of FK228 biosynthesis (Cheng et al., 2007). Primary sequence of DepH shares a 72% identity/85% similarity to a hypothetical protein (GenBank accession number ABC38333; named TdpH in our ongoing work) of *Burkholderia thailandensis* E264 (Kim et al., 2005), and shares modest percentages of identity/similarity to a few hypothetical proteins of *Pseudomonas*, *Sinorhizobium*, or *Cellvibrio* species. Neither the DepH nor the TdpH sequence has more than 34% identity/46% similarity to the deduced Ecm17 sequence of the *ecm17* gene in the triostin A/echinomycin biosynthetic gene cluster in *S. lasaliensis* (Watanabe et al., 2006). A phylogenetic analysis of the sequences of DepH and its closest homologs, and other well-studied proteins involved in disulfide bond formation in proteogenic products, suggests that an active site containing a CXXC redox motif is conserved in all related proteins; but DepH, TdpH, Ecm17 and a few hypothetical proteins constitute a distinctive clade (group 1) of proteins with a CPY/FC motif, which is clearly different from that (CAT/VC) of the thioredoxin reductase (TrxB/TrxR) family of enzymes (group 2) or that (CXXC; X represents any less conserved residue) of the Dsb-family of enzymes (group 3) (Figure 2A). Site-directed mutagenesis experiments have confirmed the catalytic essentiality of both cysteine residues in the CPYC redox motif of DepH (see Enzyme Activity and Kinetics). Furthermore, DepH can be dissected into an FAD-binding domain, an NADP⁺/NADPH-binding domain and two terminal regions, according to its organizational similarity to the TrxR of *Mycobacterium tuberculosis* (Akif et al., 2005) (Figure 2B).

Genetic Confirmation of the Involvement of *depH* in FK228 Biosynthesis

We adopted and further improved an efficient, broad host-range genetic system for gene deletion, marker removal, and gene complementation in *C. violaceum* No. 968, and potentially in a wide range of other Gram-negative bacteria (Cheng et al., 2007; see Supplemental Data available online). Subsequently we created two lines of *C. violaceum depH*[−] mutant (Table S1; Figures S1 and S2). In mutant CvΔ*depH*::FRT, a 555 bp internal part of *depH* is replaced by an FRT cassette from pPS858 (Hoang et al., 1998). Due to a concern about a potential polar effect on the functioning of downstream genes (see the *dep*




Figure 2. Sequence Analyses of DepH

(A) Phylogenetic analysis of DepH, its closest homologs, and representative bacterial proteins involved in protein/peptide disulfide bond formation. Amino acid sequences were obtained from the GenBank database, alignment was performed with ClustalW program (Chenna et al., 2003) and phylogenetic tree is presented as a rooted dendrogram. Each protein sequence is labeled by a strain name followed by a protein name where available, or by "Hp" (hypothetical protein). Database accession numbers are listed in the separate column. The redox motif (CXXC) of each protein was extracted from aligned sequences. Proteins are classified into three groups according to their phylogenetic relationships and their redox motif residues.

(B) Scheme of domain organization and the position of the redox motif of DepH.

gene cluster organization in Figure 1), we excised the *FRT* cassette from *CvΔdepH::FRT* by a site-specific Flp endonuclease encoded by vector pBMTL3-FLP2 and created a marker-free mutant *CvΔdepH* with only a 85 bp scar left at the site of gene deletion. Furthermore, we complemented this *CvΔdepH* mutant with a copy of *depH* on a medium copy-number expression vector (pBMTL3-depH), resulting in a complementant strain *CvΔdepH/pBMTL3-depH*.

Examination of FK228 production in the wild-type strain (*CvWT*), *CvΔdepH* mutant strain, *CvΔdepH/pBMTL3-depH* complementant strain, and a *CvWT/pBMTL3-depH* control strain of *C. violaceum* by liquid-chromatography mass spectrometry (LC-MS) analysis revealed very interesting results (Figure 3). First, consistent with a previous study (Cheng et al., 2007), the *CvWT* strain produced a signature profile of three FK228 ion adducts, $[M + H]^+ = 540.3$ *m/z*, $[M + Na]^+ = 563.3$ *m/z*, and $[M + K]^+ = 579.3$ *m/z*. Second, the *CvΔdepH* mutant strain produced much less FK228 (~20% of the wild-type level). When the sample extract of this strain was concentrated 5-fold and analyzed again, a shoulder ion signal peak right next to each main signal peak became noticeable. When we zoomed in, we found that those shoulder peaks had a +2 *m/z* value corresponding to each of the main signal peaks. Those signals, $[M + 2 + H]^+ = 542.4$ *m/z*, $[M + 2 + Na]^+ = 565.4$ *m/z*, and $[M + 2 + K]^+ = 581.3$ *m/z*, were apparently from an immediate FK228 precursor—the unoxidized (reduced) precursor with two free thiols (Figure 1). Furthermore,




Figure 3. Detection and Quantification of FK228 Production by LC-MS Analysis

The relative abundance of FK228 production is estimated by the sum of ion signals from three signature peaks of each strain/sample.

(A) Sample from the wild-type strain (*CvWT*).

(B) 1X and 5X concentrated samples of the *depH*-deletion mutant strain *CvΔdepH*.

(C) Sample from the *CvΔdepH/BMTL3-depH* complementant strain.

(D) Sample from the *CvWT/BMTL3-depH* control strain.

the *CvΔdepH/pBMTL3-depH* complementant strain not only regained FK228 production, but also produced about 30% more FK228 than the *CvWT* strain, indicating that the DepH-catalyzed disulfide bond formation is a rate-limiting step in FK228 biosynthesis inside the reducing environment of bacterial cells. Finally, the *CvWT/pBMTL3-depH* control strain indeed produced significantly (~34%) more FK228 than the *CvWT* strain, confirming that DepH-catalyzed disulfide bond formation is the rate-limiting step in FK228 biosynthesis.

Overexpression, Purification and Initial Characterization of DepH

DepH was overexpressed as an N-terminal 6xHis-tagged fusion protein and was purified using Ni-NTA agarose chromatography to 95% homogeneity. The yield was about 30 mg/L under the




Figure 4. Purification and Characterization of DepH

(A) Ni-NTA affinity-purified DepH was visualized on a SDS-PAGE gel. (B) The molecular mass of DepH was determined by size exclusion chromatography. Protein standards were used to generate a standard curve. The inset shows an elution profile of DepH bracketed by two protein standards. (C) UV/Vis absorbance spectra of DepH and an FAD standard. The concentrations of FAD standard and DepH were 25 μ M and 36 μ M, respectively, both in 20 mM Tris-HCl (pH 7.0) and 100 mM NaCl buffer.

conditions specified in [Experimental Procedures](#). On SDS-PAGE gel, denatured 6xHis-tagged DepH appeared to have a molecular mass of approximately 36.5 kDa (including a 2.1 kDa 6xHis tag) (Figure 4A). The minor protein band migrating slightly in front of the major band might result from weak protein cleavage at a specific point, even though a protease inhibitor cocktail was added to buffers during purification steps. Without the presence of a reducing agent in our purification scheme, DepH is expected to exist in an oxidized form with an intact disulfide bond formed at the CPYC redox motif/catalytic site (Figure 2B). By size exclusion chromatography, native 6xHis-tagged DepH was determined to have an apparent molecular mass of 71.0 kDa (Figure 4B). These results suggest that DepH exists as a homodimer under native conditions.

Identification of FAD as a Cofactor of DepH

Several lines of evidence suggested the presence of FAD cofactor in DepH. First, purified 6xHis-tagged DepH has a distinctive yellow color, indicating the presence of a flavin prosthetic group. Second, the major absorption wavelengths of DepH were at 377 nm and 455 nm, which are comparable with those of an FAD standard (Figure 4C). Third, to confirm FAD as the cofactor, DepH was denatured and the denatured protein was cleared by centrifugation. The supernatant retained the distinctive yellow color, suggesting that the suspected cofactor is not covalently bound to the protein. Subsequently, the supernatant was subjected to high-performance liquid chromatography (HPLC) analysis, along with FAD as a control. The supernatant generated a HPLC profile that is essentially identical to that of FAD standard in terms of retention time and peak shape




Figure 5. In Vitro Assays of DepH in Converting an Immediate FK228 Precursor to FK228

(A) A control reaction without DepH and kept at -80°C had $\sim 40\%$ reduced FK228 converted to FK228 due to spontaneous oxidation in prior steps. (B) Another control reaction without DepH but kept at room temperature had $\sim 60\%$ reduced FK228 converted to FK228 due to spontaneous oxidation. (C) A complete assay had 100% reduced FK228 converted to FK228 in 5 min or less at room temperature. (D) Mass spectrum of reduced FK228. (E) Mass spectrum of FK228. (F) Michaelis-Menten plot for DepH-catalyzed reactions with varying concentrations of reduced FK228 substrate. Error bars refer to standard deviation.

(Figure S3). Finally, the suspected cofactor peak was collected from HPLC and analyzed by LC-MS. The sample yielded a signal of 785.3 m/z , which is in agreement with the ion signal of FAD standard (Figure S3 inserts).

The DepH-FAD stoichiometry was approximately 1.1 to 1, suggesting that each monomeric DepH contains one molecule of FAD cofactor. This is consistent with a generalized observation regarding the flavoprotein disulfide reductase-family of enzymes (Argyrou and Blanchard, 2004).

Enzyme Activity and Kinetics

To assay the enzyme activity of DepH in catalyzing the conversion of an immediate FK228 precursor (reduced FK228) to FK228 (Figure 1), reduced FK228 was freshly prepared by reducing FK228 with an excess amount of DTT in acetonitrile/water (20% v/v), purified with preparative HPLC, dried in vacuo, and kept airtight at -20°C . Prior to assays, an appropriate amount of reduced FK228 in amorphous state was resuspended in acetonitrile to approximately 0.54 mg/ml (1.0 mM).

For qualitative assays performed in duplicate, a fixed amount of substrate (reduced FK228) was mixed with a fixed amount of enzyme (DepH) in an appropriate buffer for 5 min at room temperature in a nitrogen environment. The reaction mixture was then quenched and subjected to LC-MS analysis. Due to unavoidable spontaneous chemical oxidation during prior purification, storage, and resuspension steps, a control assay that was without enzyme and kept at -80°C had approximately 40% substrate oxidized (Figure 5A); a second control assay that was

Table 1. Relative Activities of the Wild-Type and Mutants of DepH in Converting Reduced FK228 to FK228

Enzyme	Substrates	Products	Relative Activity (%)
Blank (buffer)	Reduced FK228, NADP ⁺	–, –	0
DepH	Reduced FK228, NADP ⁺	FK228, NADPH	100
DepH-C156S	Reduced FK228, NADP ⁺	FK228, NADPH	7.5
DepH-C159S	Reduced FK228, NADP ⁺	FK228, NADPH	3.8
DepH-C156S/C159S	Reduced FK228, NADP ⁺	FK228, NADPH	3.6

without enzyme but kept at room temperature in a nitrogen gas-filled chamber had approximately 60% substrate oxidized (Figure 5B). In a complete assay, 100% of substrate was oxidized in 5 min or less (Figure 5C). The identity of reduced FK228 and FK228 (oxidized) was confirmed by subsequent LC-MS analysis (Figures 5D and 5E). Reduced FK228 with two free thiol groups is more polar, and was eluted slightly earlier than FK228.

Single point mutants (C156S or C159S) and a double mutant (C156S/C159S) of the redox motif (CPYC) of DepH were obtained by site-directed mutagenesis, and the mutant proteins were purified to homogeneity accordingly (Figure S4). The relative activities of three mutant forms of DepH compared with that of wild-type DepH were determined (Table 1). It was found that mutation of either or both cysteine residues in the redox motif resulted in a drastic reduction of activity, suggesting that both cysteine residues are critical for enzyme activity.

For steady-state kinetic assays, variable concentrations of substrate (reduced FK228) were assayed with a fixed amount of enzyme (DepH) in an appropriate buffer for variable durations of time at room temperature in a nitrogen environment. Assay reactions were stopped by mixing with iodoacetamide, which reacts with free thiol groups to form a stable adduct (Mieyal et al., 1991). This adduct of reduced FK228 was quantified by LC-MS analysis. The DepH catalytic parameters toward reduced FK228 in the presence of NADP⁺ were determined to be $V_{max} = 2.6 \pm 0.2 \mu\text{M min}^{-1}$, $K_m = 11.7 \pm 0.5 \mu\text{M}$, $k_{cat} = 1.4 \times 10^2 \pm 0.2 \text{ min}^{-1}$, and $k_{cat}/K_m = 12.0 \mu\text{M}^{-1} \cdot \text{min}^{-1}$ (Figure 5F). When NADP⁺ was replaced by NAD⁺, the K_m was measured to be $19.4 \pm 0.9 \mu\text{M}$. Therefore, NADP⁺ is a preferred electron acceptor of DepH for the reaction.

DISCUSSION

Disulfide bonds are common in proteogenic biomolecules but rare in natural products produced nonribosomally by bacteria. In proteogenic biomolecules such as proteins and peptides, disulfide bonds often serve to maintain structural integrity or to mediate redox cycling of enzyme activity (Giles et al., 2003; Kadokura et al., 2003). In natural products there are two scenarios (Figure 1). First, as seen in the quinoxaline family of antibiotics, disulfide bonds exist either as a transit stage of biosynthesis or as a part of the final static structure; they might contribute to the stability of molecules but are not critical for bioactivity. Second, as seen in FK228 and likely in spiruchostatins as well, disulfide bonds serve to not only stabilize the molecules in the form of prodrug, but also mediate the mechanism of bioactivity. In the last case, once the disulfide bond is opened by cellular reduction, a freed thiol group selectively chelates the Zn²⁺ ion of class I HDACs, thus inhibiting the enzyme activities (Nakajima

et al., 1998). Selective but modest inhibition of HDAC activities leads to a cascade of epigenetic consequences including chromatin remodeling and cancer regression (Bolden et al., 2006).

There have been extensive studies about disulfide bond formation in proteogenic biomolecules catalyzed by the thiol-disulfide oxidoreductase family of enzymes (Kadokura et al., 2003). In contrast, little is known about disulfide bond formation in natural products, particularly those of bacterial origin. In this paper, we have characterized DepH as an FAD-dependent pyridine nucleotide-disulfide oxidoreductase, specifically and efficiently catalyzing a disulfide bond formation in FK228, an epigenetically acting anticancer natural product.

Phylogenetic analysis of protein sequences classified DepH, TdpH, Ecm17, and a few hypothetical proteins into a unique group of proteins that share a conserved CPY/FC redox motif, which is different from that (CAT/VC) of the TrxB/TrxR family of thioredoxin reductases or that (CXXC) of the Dsb family of enzymes (Figure 2). Site-directed mutagenesis also confirmed the essentiality of both cysteine residues in the CPYC motif of DepH (Table 1). Therefore, the DepH-family of disulfide bond formation enzymes might represent a new class of oxidoreductases specifically involved in natural product biosynthesis. We are in the process of crystallizing DepH, solving its structure, and further elucidating the mechanism of DepH-catalyzed disulfide bond formation in FK228.

Inspired by prior knowledge about reactions catalyzed by thioredoxin reductase and thioredoxin (Lennon et al., 1999), here we propose a cascade of reactions that lead to the oxidation of the immediate FK228 precursor to afford FK228 (Figure 6). In this model, DepH is produced by bacterial cells in an oxidized form, which grabs electrons from the immediate FK228 precursor (reduced FK228) and passes the electrons through cofactor FAD on to NADP⁺/NADPH-mediated oxidative cellular processes. As a net consequence, the reduced FK228 is oxidized with the formation of a disulfide bond to become FK228. Interesting questions to be answered include how DepH is produced and maintained in the first place in an oxidized form in the reducing environment of bacterial cytoplasm, and whether mature FK228 would be reversibly reduced inside the bacterial cytoplasm and thus would require constant enzymatic maintenance.

Deletion of *depH* led to a drastic decrease of FK228 production by the *CvΔdepH* mutant strain, which confirmed the critical role of *depH* in FK228 biosynthesis (Figure 3). The notably increased accumulation of an immediate FK228 precursor with positive ion signals of $[M + 2 + H/Na/K]^+ m/z$ in the extract of this mutant strain suggests that the immediate FK228 precursor contains two free thiol groups and that the oxidative conversion from this precursor to FK228 is indeed




Figure 6. Proposed Sequence of Oxidation-Reduction Reactions in the Final Step of FK228 Biosynthesis

Abbreviations or symbols: FK228=(SH)₂, the reduced form of FK228 (immediate FK228 precursor); FK228=(S-S), the oxidized (natural) form of FK228; DepH=(SH)₂, the reduced form of DepH; DepH=(S-S), the oxidized form of DepH; FAD_{ox}, the oxidized form of FAD; FAD_{red}, the reduced form of FAD.

the final step in FK228 biosynthesis. Apparently it takes a dedicated DepH catalyst to efficiently convert the precursor into FK228 inside the reducing environment of bacterial cells. Nevertheless, the mutant still produced about 20% as much FK228 as the wild-type strain. A plausible explanation is that spontaneous chemical oxidation could slowly convert the precursor into FK228, despite the reducing microenvironment of bacterial cells.

However, why is the immediate FK228 precursor in the mutant strain not accumulated to a level comparable to the FK228 level in the wild-type strain? We speculate that the precursor with free thiol groups might be liable to hydrolysis inside or outside of bacterial cells, or the precursor might be toxic to bacterial cells by allowing the free thiol groups to interact with some of the hundreds of Zn²⁺-containing enzymes (Blencowe and Morby, 2003). If the later speculation were proven true, it could explain why the *C. violaceum* no. 968 strain produces FK228 in the form of a prodrug, because prodrug FK228 with an intact disulfide bond is stable, inert, and nontoxic. Prodrug strategy has become a privileged scheme in modern drug development for improving physicochemical, biopharmaceutical, or pharmacokinetic properties of pharmacologically active agents (Rautio et al., 2008).

The promising anticancer activities of FK228 and the unique role of DepH in FK228 biosynthesis entitle the use of the DepH sequence as bait for genome mining of new biosynthetic gene clusters that might produce additional FK228-like natural products. In fact, we have identified a strong homolog of DepH that we named TdpH (GenBank accession number ABC38333), which is putatively encoded by a gene (*BTH_I2359*) in the published genome of *B. thailandensis* E264 (Kim et al., 2005). DepH and TdpH sequences share a 72% identity/85% similarity. The TdpH-encoding gene is located within a cryptic biosynthetic gene cluster that shares striking similarity to the FK228 biosynthetic gene cluster, and our laboratory is currently exploring this finding for the discovery of FK228-like compounds from *B. thailandensis* E264.

Furthermore, DepH, TdpH, and Ecm17 are the only known or proposed enzymes involved in disulfide bond formation in natural products; therefore, their genes can be exploited in biosynthetic pathway engineering schemes for the formation of disulfide bonds in new drug molecules. Similarly, the DepH, TdpH, and Ecm17 proteins can be exploited in chemoenzymatic synthesis schemes for in vitro conversion of synthetic precursors containing two free thiol groups into final products with a disulfide bond.

Finally, disulfide bond formation in FK228 biosynthesis appeared to be a rate-limiting step; overexpression of *depH* has led to an increased yield of FK228 in the CvΔ*depH*/pBMTL3-

depH complementant strain as well as in the wild-type control strain CvWT/pBMTL3-*depH* (Figure 3). This finding provides opportunities for improving the yield of FK228 or related natural products by genetic engineering.

SIGNIFICANCE

The biochemistry of disulfide bond formation in nonribosomally produced natural products, including some important anticancer agents, is largely unknown. In this work, we genetically confirmed the involvement of *depH* in the biosynthesis of FK228, an epigenetically acting anticancer natural product produced by *Chromobacterium violaceum* no. 968, and we biochemically characterized DepH as an FAD-dependent pyridine nucleotide-disulfide oxidoreductase, specifically and efficiently catalyzing a disulfide bond formation in FK228. Sequence analysis suggested that DepH contains a signature redox motif CPYC, a conserved FAD-binding domain, and an NADP⁺/NADPH-binding domain. When either or both cysteine residues in the redox motif were mutated, the protein lost most of its catalytic activity. We speculate that this motif might represent a subfamily of disulfide oxidoreductases specifically involved in secondary metabolism. We further showed that deletion of *depH* led to a drastic decrease of FK228 production, while the relative abundance of the immediate FK228 precursor increased notably. Interestingly, complementation of the *depH*-deletion mutant with *depH* restored FK228 production to a level 30% higher than that of the wild-type strain. Additionally, we showed that purified 6xHis-tagged DepH protein in native form is a homodimer of 71.0 kDa, with each monomer contains one molecule of FAD cofactor. Finally we showed that DepH can efficiently convert the immediate FK228 precursor into FK228 in the presence of an NADP⁺ electron acceptor, and the catalytic parameters are $V_{max} = 2.6 \pm 0.2 \mu\text{M min}^{-1}$, $K_m = 11.7 \pm 0.5 \mu\text{M}$, $k_{cat} = 1.4 \times 10^2 \pm 0.2 \text{ min}^{-1}$, and $k_{cat}/K_m = 12.0 \mu\text{M}^{-1} \cdot \text{min}^{-1}$. To the best of our knowledge, this work represents the first biochemical characterization of an enzyme involved in disulfide bond formation in a nonribosomally produced bacterial natural product.

EXPERIMENTAL PROCEDURES

Bacterial Strains, Media, and Growth Conditions

Bacterial strains and plasmids used in this study are summarized in Table S1. All chemicals, biochemicals, and media components were purchased from Fisher Scientific (Pittsburgh, PA), unless otherwise indicated. *C. violaceum* no. 968 and *E. coli* strains were maintained, cultivated, and genetically manipulated as described elsewhere (Cheng et al., 2007), except that only 1% (w/v)

Diaion HP-20 (Supelco, Bellefonte, PA) resin was added to fermentation medium to absorb bacterial byproducts.

DNA Manipulation, PCR, Cloning, and Sequencing

General DNA manipulations were performed according to standard protocols (Sambrook and Russell, 2000). Bacterial genomic DNA was extracted with an UltraClean microbial DNA isolation kit from MO BIO Labs (Carlsbad, CA). DNA modification enzymes and restriction enzymes were purchased from New England BioLabs (Ipswich, MA). Oligonucleotide primers were ordered from Operon (Huntsville, AL). QIAprep plasmid purification kit and QIAEX II gel extraction kit were from QIAGEN (Valencia, CA). Polymerase chain reaction (PCR) was performed on a DNA Engine Dyad thermocycler (Bio-Rad, Hercules, CA). DNA sequencing was performed with an ABI 3730 automated DNA sequencer (Applied Biosystems, Foster City, CA) at the University of Wisconsin-Madison Biotechnology Center.

Gene Deletion, FRT Cassette Removal, and Gene Complementation

The general scheme of using a broad host-range Flp-FRT recombination system for site-specific gene replacement/deletion and marker removal has been described elsewhere (Choi and Schweizer, 2005; Hoang et al., 1998), but was modified in this study (Figures S1 and S2).

To construct a *depH*-gene replacement vector, two DNA fragments (amplicons) were first amplified by PCR from total DNA of the wild-type *C. violaceum* no. 968 strain: a 470 bp 5'-end of *depH* gene fragment (amplicon 1) was amplified with primer set KpnI-*depH*-UpF (5'-AGGTACCGGGATTCGTCGCTGTTG C-3') and FRT-F-*depH*-UpR (5'-TCAGAGCGCTTTTGAAGCTAATTCGATCAC CAGCAGCGGC-3'), a 460 bp 3'-end of *depH* gene fragment (amplicon 2) was amplified with primer set FRT-R-*depH*-DnF (5'-AGGAACCTCAAGATCCCCAA TTCGACGGGCTGTTACGATG-3') and BamHI-*depH*-DnR (5'-AGGATCCGC GCGGCGGCTTTGC-3'), and a 1.8 kb FRT cassette containing a *Gm^r* marker gene and a GFP reporter gene flanked by two FRT recognition sequences (amplicon 3) was amplified from pPS858 with primer set FRT-F (5'-CGAATTAG CTTCAAAAGCGCTCTGA-3') and FRT-R (5'-CGAATTGGGGATCTTGAAGTTC CT-3'). Amplicons 1–3 were assembled into a 2.7 kb amplicon 4 by multiplex PCR using Long Amp DNA polymerase. Amplicon 4 was digested with KpnI/BamHI and the insert was subsequently cloned into suicide vector pEX10Tc to make a *depH*-gene replacement vector pYC04-18.

To create a *depH*-gene replacement mutant of *C. violaceum*, pYC04-18 was first transformed into *E. coli* S17-1 cells, which subsequently passed the vector to *C. violaceum* cells via interspecies conjugation. Mutant strains of *C. violaceum* with *depH* partially replaced by the FRT cassette were selected on LB agar supplemented with 200 µg/ml ampicillin (Ap; *C. violaceum* is naturally resistant to Ap up to 500 µg/ml), 50 µg/ml gentamicin, and 5% (w/v) sucrose at 30°C. The genotype of independent mutants was verified by colony PCR using the primer set *depH*-F (5'-CGACGTCATCGTGATCGGCGGC-3') and *depH*-R (5'-CATTTCTGAGCGGTGACGC-3') (Figure S2A). One representative mutant strain was saved and named CvΔ*depH*::FRT.

To create a marker-free mutant by removing the FRT cassette from CvΔ*depH*::FRT, a broad host-range Flp-expression vector was first constructed. A 5.16 kb SacI/SphI fragment containing the *cl857* < *P_{ts}*-*P₂* > *flp*-*P_{sac}* > *sacB* genetic determinants was excised from pFLP2, blunt ended, and cloned into the EcoRV site of pBMTL-3 to make pBMTL3-FLP2. This vector replicates in a broad range of bacterial hosts at or above 37°C and expresses a site-specific Flp endonuclease. Vector pBMTL3-FLP2 was introduced into CvΔ*depH*::FRT by electroporation and marker-free mutants were selected on LB agar supplemented with 200 µg/ml Ap and 25 µg/ml chloramphenicol (Cm) at 37°C. Vector pBMTL3-FLP2 was subsequently cured from the mutants by streaking for two rounds on LB agar supplemented with 200 µg/ml Ap and 5% (w/v) sucrose at 30°C. The genotype of independent gene-deletion mutants was verified by colony PCR using the primer set *depH*-F and *depH*-R (Figure S2B). One final representative marker-free mutant strain was saved and named CvΔ*depH*.

To complement the CvΔ*depH* mutant and CvWT strain (as control) with a functional *depH* gene on a vector, the entire *depH* ORF (960 bp) was amplified from genomic DNA with primer set *depH*-exp-FP (5'-GTCTAGACATATGA AGGCGCGCGCGCG-3') and *depH*-exp-RP (5'-GCAAGCTTTTACCCGAAC ACCAACTTGCG-3'). This product was digested with NdeI/HindIII and the insert was cloned into pET29a to make pET29a-*depH* intermediate construct.

The *depH* ORF along with an upstream ribosomal binding site from the vector was excised by XbaI/HindIII digestion from pET29a-*depH* and cloned into pBMTL-3 to make the final *depH* complementation vector pBMTL3-*depH*. The gene fidelity was verified by resequencing and the vector was introduced by conjugation into CvΔ*depH* mutant to create a complementation strain CvΔ*depH*/pBMTL3-*depH* and into CvWT to create a control strain CvWT/pBMTL3-*depH*.

Bacterial Fermentation, Extraction, Identification, and Quantification of FK228, and Preparation of Reduced FK228

Fermentation of the CvWT strain, CvΔ*depH* mutant strain, CvΔ*depH*/pBMTL3-*depH* complementant strain, and CvWT/pBMTL3-*depH* control strain of *C. violaceum* in 50 ml nutrient broth supplemented with 200 µg/ml Ap, 1% (w/v) of Diaion HP-20 resins, and with 0.5% (v/v) lactose (lactose induces the expression of *depH* on the pBMTL-3 vector) for 4 days at 30°C, was performed similarly as described elsewhere (Cheng et al., 2007). After fermentation resins and cell debris of each strain were collected by centrifugation and lyophilized to dryness. Ten ml of ethyl acetate was used to extract the dried mass and 20 µl of such organic extract was analyzed with an Agilent 1100 series LC/MSD Trap mass spectrometer (Agilent, Santa Clara, CA) for the detection and quantification of FK228 production by relating the peak area of ion signals to that of FK228 standard, as described elsewhere (Cheng et al., 2007; Hwang et al., 2004).

A larger quantity of FK228 was purified from 15 L fermentation culture of wild-type *C. violaceum* according to a previously published procedure (Ueda et al., 1994), and saved as amorphous powder at −20°C until use. To prepare for the immediate FK228 precursor (reduced FK228 with two free thiols), a proper amount of FK228 was redissolved in acetonitrile/water (20% v/v) and mixed overnight at room temperature with 50 mM DTT. Reduced FK228 (almost 100% reduction) was purified from reaction mixture by preparative HPLC on a ProStar HPLC system (Varian, Walnut Creek, CA) with a 10 µm particle size, 21.2 × 250 mm Prep-C18 column (Agilent). A gradient from 100% buffer A (20% acetonitrile) to 100% buffer B (100% acetonitrile) was achieved in 30 min. The fraction containing the reduced FK228 was lyophilized and stored airtight at −20°C until use. Reduced FK228 was readily redissolved in acetonitrile to make suitable concentrations of substrate solution for enzymatic assays.

DepH Overexpression and Purification, and Site-Directed Mutagenesis

The previously amplified *depH* ORF (960 bp) was cloned into the NdeI/HindIII sites of pET28a to make pCW01-1212 in *E. coli* DH5α cells. The DNA fidelity was verified by sequencing and the vector was introduced into *E. coli* BL21(DE3) cells for protein overexpression and purification.

E. coli BL21(DE3)/pCW01-1212 was cultured in 4 L LB medium supplemented with 50 µg/ml kanamycin at 37°C to reach an OD₆₀₀ of 0.6. Then IPTG was added to a final concentration of 0.05 mM to induce gene expression and the cells were further cultured at 28°C for 12 hr. Cells were harvested by centrifugation and resuspended in 50 ml lysis buffer (50 mM phosphate [pH 7.0], 300 mM NaCl, 0.1% [v/v] Tween-20, and two complete EDTA free protease inhibitor cocktail tablets [Roche, Indianapolis, IN]). Cells were broken by passing twice through a French Press (Sim-Aminco) and cell lysate was clarified by centrifugation at 48,400 g for 30 min at 4°C. The resulting supernatant was loaded on a Ni-NTA agarose column (QIAGEN) that was equilibrated with a wash buffer (50 mM phosphate [pH 7.0], 300 mM NaCl, and 20 mM imidazole) and the column was washed extensively with the same wash buffer. DepH was eluted with an elution buffer (50 mM phosphate [pH 7.0], 300 mM NaCl, and 250 mM imidazole). The purified protein was dialyzed using a 6–8 kDa Spectra/Pro membrane tubing (Spectrum; Gardena, GA) at 4°C against a storage buffer (20 mM Tris-HCl [pH 7.0], and 100 mM NaCl) overnight. Because DepH is expected to exist naturally in an oxidized form with an intact disulfide bond, no reducing agent (e.g., DTT or 2-mercaptoethanol) was added to the purification steps. The purity of DepH was assessed by SDS-PAGE and the protein concentration was determined by Bradford assay (Bradford, 1976), using bovine serum albumin as a standard. Finally aliquots of DepH were flash frozen and stored at −80°C until use.

Site-directed mutagenesis to create single mutants (C156S or C159S) and a double mutant (C156S/C159S) of DepH were accomplished using the Quik-Change Lightning Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and the following primer pairs (where underlined letters indicate base

change): C156S-F (5'-GGAAAGCGTGTTCCTACTCCCTTACTGCCACG-3') and C156S-R (5'-CGTGGCAGTAAGGGGAGTGAACACGCTTTCC-3'), C159S-F (5'-CACTGCCCTTACTCCACGGCTACGAACG-3') and C159S-R (5'-CAGTTCGTAGCCGTGGGAGTAAGGGCAGTGG-3'), and C156S/C159S-F (5'-GCGTGTTCCTACTCCCTTACTCCACGGCTACG-3') and C156S/C159S-R (5'-CGTAGCCGTGGGAGTAAGGGGAGTGAACACGC-3'). Mutated *depH* genes based on pCW01-1212 were verified by sequencing, and mutant proteins were purified with the same procedure as for the wild-type DepH.

Determination of Physical and Biochemical Properties of DepH

The oligomeric status of DepH was determined by size exclusion chromatography at 4°C using the ÄKTA Prime FPLC equipped with a HiPrep Sephacryl 26/60 S300 high-resolution column (GE Life Sciences, Piscataway, NJ). Running buffer used was 20 mM Tris-HCl (pH 7.0) and 100 mM NaCl, and the flow rate was 0.5 ml/min. Protein elution was monitored at UV₂₈₀. To establish a reference curve, gel-filtration molecular weight markers (Sigma-Aldrich) including blue dextran (2000 kDa), amylase from sweet potato (200 kDa), alcohol dehydrogenase from yeast (150 kDa), bovine serum albumin (66 kDa), carbonic anhydrase from bovine (29 kDa), and cytochrome c from horse heart (12.4 kDa) were used. DepH was analyzed separately or in combination with some markers under the same conditions.

Ultraviolet and visible (UV/Vis) spectra of DepH (36 μM in 20 mM Tris-HCl [pH 7.0] and 100 mM NaCl buffer) and FAD standard (25 μM in the same buffer) from 200 to 800 nm were obtained sequentially with Cary 100 Bio spectrophotometer (Varian, Walnut Creek, CA) at room temperature.

The presence of FAD cofactor in DepH was determined by HPLC and LC-MS analysis. Separation of sample was performed on a ProStar HPLC system from Varian, equipped with the Eclipse XBD C18 column (5 μm particle size, 4.6 × 250 mm) from Agilent. Flow rate was maintained at 1 ml/min and the column was equilibrated with a buffer mixture of 85% solvent A (5 mM ammonium acetate [pH 6.5]/15% solvent B [100% methanol]). DepH (36 μM) was denatured by boiling at 100°C for 5 min to free the cofactor. Denatured protein was removed by centrifugation and 20 μl supernatant was analyzed by HPLC. A linear gradient from the equilibration stage to a final buffer composition of 25% solvent A/75% solvent B was achieved in 20 min. The ultraviolet irradiation absorbance of cofactor was monitored at 264 nm. An HPLC fraction containing the cofactor was dried in vacuo, resuspended in 50 μl acetonitrile, and examined by LC-MS analysis. FAD standard (25 μM) was used as a reference.

The stoichiometry of DepH-FAD was determined in duplicate as follows. An aliquot of DepH (36 μM) was saturated with an excess amount of FAD (1 mM) at 4°C overnight and was then dialyzed against the storage buffer (20 mM Tris-HCl [pH 7.0], and 100 mM NaCl) to remove unbound FAD. DepH concentration was redetermined using Bradford assay. DepH was subsequently denatured by boiling for 5 min to release bound FAD. FAD concentration was determined from the absorption at 450 nm, measured on a Cary 100 Bio spectrophotometer (Varian) at room temperature, using a molar extinction coefficient of $A_{450} = 11.0 \text{ mM}^{-1} \cdot \text{cm}^{-1}$. Buffer was used as a blank for background subtraction.

Determination of Enzyme Activity and Enzyme Kinetics

Enzyme Activity of the Wild-Type and Mutated Forms of DepH

First, the reaction buffer (20 mM Tris-HCl [pH 7.0], 100 mM NaCl, with 200 μM NADP⁺) used in assays was purged extensively with bubbling of nitrogen gas. For a complete assay, 5 μl reduced FK228 (~100 μM) and 1 μl enzyme solution (36 μM) were added into 95 μl reaction buffer and the reaction was allowed to proceed for 5 min at room temperature in a nitrogen-gas-filled chamber. Each reaction was quenched with 400 μl ice-cold acetone for 5 min on ice. Acetone was then removed by a flow of nitrogen gas and the remaining solution was analyzed with LC-MS. Enzyme was omitted from control reactions, which were kept either in a -80°C freezer or at room temperature, and received the same treatment as the complete reaction until LC-MS analysis. The total time needed from the start of reaction to LC-MS analysis was about 20 min. All reactions were assayed in duplicate.

Enzyme Kinetics of DepH

Due to a high rate of reaction and unavoidable spontaneous chemical oxidation, the assay conditions were optimized by numerous tests (data not shown). The reactions were performed in 30 μl buffer (20 mM Tris-HCl [pH 7.0], 100 mM

NaCl, 200 μM NADP⁺ or NAD⁺) at room temperature in a nitrogen-gas-filled chamber. Variable concentration of substrate (reduced FK228, from 2 to 80 μM final concentration) and fixed amount of enzyme DepH (0.02 μg; 18 nM final concentration) was added into each reaction. Five microliters of 500 mM iodoacetamide was used to stop reactions and to block free thiol groups at different time points (0, 0.5, 1, 2, and 4 min). Afterwards, 20 μl of each reaction mixture was analyzed with LC-MS. All reactions were assayed in duplicate. Values from the 0 min time point were used for background subtraction.

ACCESSION NUMBERS

The sequence reported in this article has been deposited into GenBank under accession number [EF210776](#) (Cheng et al., 2007).

SUPPLEMENTAL DATA

Supplemental Data include one table and four figures and can be found with this article online at [http://www.cell.com/chemistry-biology/supplemental/S1074-5521\(09\)00152-5](http://www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00152-5).

ACKNOWLEDGMENTS

We thank Herbert Schweizer for providing vectors pPS858, pEX18Tc, and pFLP2, and Ryan Gill for providing vector pBMTL-3. We thank Patrick Anderson for assistance with LC-MS, and Daad Saffarini for assistance with lysis of cells on a French press. We further thank Michael Thomas for critical reading of the manuscript, and we appreciate anonymous reviewers' helpful comments. This work was supported by a University of Wisconsin-Milwaukee Research Growth Initiative Award and by a US Department of Defense Breast Cancer Research Program Idea Award W81XWH-08-1-0673.

Received: January 13, 2009

Revised: April 23, 2009

Accepted: May 8, 2009

Published: June 25, 2009

REFERENCES

- Akif, M., Suhre, K., Verma, C., and Mande, S.C. (2005). Conformational flexibility of *Mycobacterium tuberculosis* thioredoxin reductase: crystal structure and normal-mode analysis. *Acta Crystallogr. D Biol. Crystallogr.* 61, 1603–1611.
- Argyrou, A., and Blanchard, J.S. (2004). Flavoprotein disulfide reductases: advances in chemistry and function. *Prog. Nucleic Acid Res. Mol. Biol.* 78, 89–142.
- Bardwell, J.C., McGovern, K., and Beckwith, J. (1991). Identification of a protein required for disulfide bond formation in vivo. *Cell* 67, 581–589.
- Blencowe, D.K., and Morby, A.P. (2003). Zn(II) metabolism in prokaryotes. *FEMS Microbiol. Rev.* 27, 291–311.
- Bolden, J.E., Peart, M.J., and Johnstone, R.W. (2006). Anticancer activities of histone deacetylase inhibitors. *Nat. Rev. Drug Discov.* 5, 769–784.
- Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72, 248–254.
- Bryk, R., Lima, C.D., Erdjument-Bromage, H., Tempst, P., and Nathan, C. (2002). Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. *Science* 295, 1073–1077.
- Cheng, Y.Q., Yang, M., and Matter, A.M. (2007). Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in *Chromobacterium violaceum* No. 968. *Appl. Environ. Microbiol.* 73, 3460–3469.
- Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T.J., Higgins, D.G., and Thompson, J.D. (2003). Multiple sequence alignment with the Clustal series of programs. *Nucleic Acids Res.* 31, 3497–3500.

- Choi, K.H., and Schweizer, H.P. (2005). An improved method for rapid generation of unmarked *Pseudomonas aeruginosa* deletion mutants. *BMC Microbiol.* 5, 30.
- Dawson, S., Malkinson, J.P., Paumier, D., and Searcey, M. (2007). Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies. *Nat. Prod. Rep.* 24, 109–126.
- Giles, N.M., Watts, A.B., Giles, G.I., Fry, F.H., Littlechild, J.A., and Jacob, C. (2003). Metal and redox modulation of cysteine protein function. *Chem. Biol.* 10, 677–693.
- Hoang, T.T., Karkhoff-Schweizer, R.R., Kutchma, A.J., and Schweizer, H.P. (1998). A broad-host-range Flp-*FRT* recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* 212, 77–86.
- Hwang, K., Piekarz, R.L., Bates, S.E., Figg, W.D., and Sparreboom, A. (2004). Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 809, 81–86.
- Jacob, C. (2006). A scent of therapy: pharmacological implications of natural products containing redox-active sulfur atoms. *Nat. Prod. Rep.* 23, 851–863.
- Kadokura, H., Katzen, F., and Beckwith, J. (2003). Protein disulfide bond formation in prokaryotes. *Annu. Rev. Biochem.* 72, 111–135.
- Kim, H.S., Schell, M.A., Yu, Y., Ulrich, R.L., Sarria, S.H., Nierman, W.C., and DeShazer, D. (2005). Bacterial genome adaptation to niches: divergence of the potential virulence genes in three *Burkholderia* species of different survival strategies. *BMC Genomics* 6, 174.
- Lennon, B.W., Williams, C.H., Jr., and Ludwig, M.L. (1999). Crystal structure of reduced thioredoxin reductase from *Escherichia coli*: structural flexibility in the isoalloxazine ring of the flavin adenine dinucleotide cofactor. *Protein Sci.* 8, 2366–2379.
- Lombo, F., Velasco, A., Castro, A., de la Calle, F., Brana, A.F., Sanchez-Puelles, J.M., Mendez, C., and Salas, J.A. (2006). Deciphering the biosynthesis pathway of the antitumor thiocoraline from a marine actinomycete and its expression in two streptomyces species. *ChemBioChem* 7, 366–376.
- Martin, J.L., Bardwell, J.C., and Kuriyan, J. (1993). Crystal structure of the DsbA protein required for disulphide bond formation in vivo. *Nature* 365, 464–468.
- Masakuni, O., Toshio, G., Takashi, F., Yasuhiro, H., and Hirotugu, U. (1991). FR901375 substance and production thereof. JP3141296 (A).
- Masuoka, Y., Nagai, A., Shin-ya, K., Furihata, K., Nagai, K., Suzuki, K., Hayakawa, Y., and Seto, H. (2001). Spiruchostatins A and B, novel gene expression-enhancing substances produced by *Pseudomonas* sp. *Tetrahedron Lett.* 42, 41–44.
- Mieyal, J.J., Starke, D.W., Gravina, S.A., and Hocevar, B.A. (1991). Thioltransferase in human red blood cells: kinetics and equilibrium. *Biochemistry* 30, 8883–8891.
- Nakajima, H., Kim, Y.B., Terano, H., Yoshida, M., and Horinouchi, S. (1998). FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. *Exp. Cell Res.* 241, 126–133.
- Nakamoto, H., and Bardwell, J.C. (2004). Catalysis of disulfide bond formation and isomerization in the *Escherichia coli* periplasm. *Biochim. Biophys. Acta* 1694, 111–119.
- Nogle, L.M., and Gerwick, W.H. (2002). Somocystinamide A, a novel cytotoxic disulfide dimer from a Fijian marine cyanobacterial mixed assemblage. *Org. Lett.* 4, 1095–1098.
- Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Jarvinen, T., and Savolainen, J. (2008). Prodrugs: design and clinical applications. *Nat. Rev. Drug Discov.* 7, 255–270.
- Sambrook, J., and Russell, D.W. (2000). *Molecular Cloning: A Laboratory Manual*, Third Edition (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory).
- Shigematsu, N., Ueda, H., Takase, S., Tanaka, H., Yamamoto, K., and Tada, T. (1994). FR901228, a novel antitumor bicyclic depsipeptide produced by *Chromobacterium violaceum* No. 968. II. Structure determination. *J. Antibiot. (Tokyo)* 47, 311–314.
- Tang, G.L., Cheng, Y.Q., and Shen, B. (2004). Leinamycin biosynthesis revealing unprecedented architectural complexity for a hybrid polyketide synthase and nonribosomal peptide synthetase. *Chem. Biol.* 11, 33–45.
- Ueda, H., Manda, T., Matsumoto, S., Mukumoto, S., Nishigaki, F., Kawamura, I., and Shimomura, K. (1994). FR901228, a novel antitumor bicyclic depsipeptide produced by *Chromobacterium violaceum* No. 968. III. Antitumor activities on experimental tumors in mice. *J. Antibiot. (Tokyo)* 47, 315–323.
- Waksman, G., Krishna, T.S., Williams, C.H., Jr., and Kuriyan, J. (1994). Crystal structure of *Escherichia coli* thioredoxin reductase refined at 2 Å resolution. Implications for a large conformational change during catalysis. *J. Mol. Biol.* 236, 800–816.
- Watanabe, K., Hotta, K., Praseuth, A.P., Koketsu, K., Migita, A., Boddy, C.N., Wang, C.C., Oguri, H., and Oikawa, H. (2006). Total biosynthesis of antitumor nonribosomal peptides in *Escherichia coli*. *Nat. Chem. Biol.* 2, 423–428.
- Yoo, C.B., and Jones, P.A. (2006). Epigenetic therapy of cancer: past, present and future. *Nat. Rev. Drug Discov.* 5, 37–50.

SUPPLEMENTARY DATA

An FAD-Dependent Pyridine Nucleotide-Disulfide Oxidoreductase Is Involved in Disulfide Bond Formation in FK228 Anticancer Depsipeptide

Cheng Wang, Shane R. Wesener, Hailong Zhang, and Yi-Qiang Cheng

TABLE S1. Bacterial Strains and Plasmids Used in This Study

Strains or Plasmids	Description	Source or Reference
<i>Chromobacterium violaceum</i> strains		
No. 968 (= FERM BP-1968)	Wild type strain, FK228 producer, Ap ^r Thio ^{ra}	IPOD ^b (Ueda et al., 1994)
CvΔdepH::FRT	Mutant strain with an internal part of the <i>depH</i> replaced by an <i>FRT</i> cassette (<i>Gm^r GFP</i>) from pPS858	This study
CvΔdepH	Mutant strain derived from CvΔdepH::FRT with the <i>FRT</i> cassette excised	This study
CvWT/pBMTL3-depH	Wild type strain harboring a <i>depH</i> complementation vector pBMTL3-depH	This study
CvΔdepH/pBMTL3-depH	Mutant strain CvΔdepH harboring a <i>depH</i> complementation vector pBMTL3-depH	This study
<i>Escherichia coli</i>		
DH5α	General cloning host	Laboratory stock
S17-1	Host strain for interspecies conjugation	Laboratory stock
BL21(DE3)	Host strain for protein expression	Novagen (Madison, WI)
Plasmids		
Cosmid 8	Cosmid clone containing the FK228 biosynthetic gene cluster (<i>dep</i>) and flanking regions; Ap ^r Kan ^r	(Cheng et al., 2007)
pPS858	Source of the <i>FRT</i> cassette; Ap ^r Gm ^r GFP ⁺	(Hoang et al., 1998)
pEX18Tc	Gene replacement vector; conjugative; Tc ^r oriT <i>sacB</i> ⁺	(Hoang et al., 1998)
pYC04-18	<i>depH</i> gene replacement construct based on pEX18Tc	This study
pFLP2	Vector that produces a Flp endonuclease specifically recognizes the <i>FRT</i> site; Ap ^r oriT <i>sacB</i> ⁺	(Hoang et al., 1998)
pBMTL-3	Broad host-range gene expression vector; conjugative; Cm ^r mob pLac	(Lynch and Gill, 2006)
pBMTL3-FLP2	A broad host-range Flp-expression vector based on pFLP2 and pBMTL-3	This study
pET28a and pET29a	Vectors for protein overexpression; Ap ^r Kan ^r	Novagen
pET29a-depH	Intermediate vector with <i>depH</i> cloned at NdeI/HindIII sites of pET29a	This study
pBMTL3-depH	<i>depH</i> gene complementation vector based on pBMTL-3	This study
pCW01-1212	DepH overexpression vector with <i>depH</i> cloned at NdeI/HindIII sites of pET28a	This study

^a Thio^r, thiostrepton resistance.

^b IPOD, International Patent Organism Depository, Tsukuba, Japan.






Figure S1. Maps of Vectors and Constructs

Suicide vector pEX18Tc (Hoang et al., 1998) was used to carry a chimeric cassette (Figure S2) for gene deletion of *depH*. Vector pFLP2 (Hoang et al., 1998) was the donor for *sacB-FLP* gene cassette. Vector pBMTL-3 (Lynch and Gill, 2006) was used to create a Flp-expression vector pBMTL3-FLP2 and a gene complementation vector pBMTL3-depH. All maps were drawn with Vector-NTI software (Invitrogen, Carlsbad, CA). The sizes of gene/vector are not necessarily in scale.

A**B****Figure S2. Deletion of an Internal Part of *depH***

(A) Scheme of multiplex PCR for the construction of a gene deletion vector and subsequent creation of mutant strains. (B) PCR examination of the genotype of the wild type and mutant strains of *C. violaceum* No. 968. Lane 1, 1-kb DNA marker; Lane 2: wild type strain (1.0-kb PCR product); Lane 3: vector pYC04-18 (2.4-kb PCR product); Lane 4: CvΔ*depH*::FRT mutant strain (2.4-kb PCR product); Lane 5: CvΔ*depH* mutant strain (0.6-kb PCR product). Due to secondary structures formed by the highly homologous *FRT* recognition sequences, PCRs typically generate certain level of background.




Figure S3. Identification of FAD as a Cofactor of DepH.

HPLC profile and mass spectrum of the extracted FAD cofactor from DepH in comparison with those of FAD standard. Both the HPLC retention time and the ion signal of subjects are almost identical.




Figure S4. Purified Wild Type (DepH-WT) and Mutant Proteins (C156S, C159S and C156S/C159S) of DepH Visualized by SDS-PAGE Gel. M, molecular weight standards (kDa).

Supplemental References

Cheng, Y.Q., Yang, M., and Matter, A.M. (2007). Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in *Chromobacterium violaceum* No. 968. *Applied and environmental microbiology* 73, 3460-3469.

Hoang, T.T., Karkhoff-Schweizer, R.R., Kutchma, A.J., and Schweizer, H.P. (1998). A broad-host-range Flp-*FRT* recombination system for site-specific excision of chromosomally-located

DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* 212, 77-86.

Lynch, M.D., and Gill, R.T. (2006). Broad host range vectors for stable genomic library construction. *Biotechnology and bioengineering* 94, 151-158.

Ueda, H., Manda, T., Matsumoto, S., Mukumoto, S., Nishigaki, F., Kawamura, I., and Shimomura, K. (1994). FR901228, a novel antitumor bicyclic depsipeptide produced by *Chromobacterium violaceum* No. 968. III. Antitumor activities on experimental tumors in mice. *The Journal of antibiotics* 47, 315-323.